# Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC

> **NCT04754815** · PHASE2 · WITHDRAWN · sponsor: **Shirish Gadgeel**

## Conditions studied

- Non Small Cell Lung Cancer
- Advanced Lung Non-Small Cell Carcinoma
- PD-L1 Gene Mutation

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Pemetrexed
- **DRUG:** Paclitaxel
- **DRUG:** Nab-paclitaxel
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT04754815
- **Lead sponsor:** Shirish Gadgeel
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-04-01
- **Primary completion:** 2025-04-01
- **Final completion:** 2026-04-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Logistical challenges primarily due to COVID led to delay in starting the study and now is not felt to be clinically relevant.
- **Last updated:** 2022-03-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04754815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04754815, "Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04754815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*